of novel cancer drugs approved over the past 11 years are used with a curative intent or provide a survival benefit in the palliative care setting. However, the monthly cost for agents not providing these benefits was higher, indicating a disconnect between efficacy and cost.
OBJECTIVES:
To estimate the cost-effectiveness of temsirolimus as a treatment option in poor risk renal cell carcinoma compared with interferon-␣ and from the perspective of national health insurance in Taiwan. METHODS: A decision-analytic model was developed to estimate the cost effectiveness of temsirolimus. Cost and the clinical effectiveness data were obtained from published literature and current reimbursed price published by Bureau of National Health Insurance. All costs and outcomes were discounted at an annual rate of 3%. The effect of parameter uncertainty on cost-effectiveness was explored through extensive one-way and probabilistic sensitivity analyses. RESULTS: Compared with interferon-a, temsirolimus treatment resulted in an discounted incremental cost per QALY gained of NT$ 4,775,609, based on an estimated mean gain of 0.24 quality-adjusted life years (QALYs) per patient; and a cost per life-year gain of NT$ 2,512,048. Cost-effectiveness estimates were most sensitive to changes in hazard ratios for overall survival between temsirolimus and interferon-a. CONCLUSIONS: In comparison with interferon-a, the ICER (NT$4,775,609) for temsirolimus as a treatment in poor risk renal cell carcinoma, was found to be much higher than the threshold suggested by the World Health Organization. Therefore, temsirolimus could not be regarded as a cost-effective option from the National Health Insurance perspective. 
PCN20 COMPARATIVE EFFICACY AND ECONOMIC EVALUATION OF DACARBAZINE AND TEMOZOLOMIDE IN TREATMENT OF MALIGNANT MELANOMA IN IRAN

OBJECTIVES:
The worldwide incidence of melanoma is increasing rapidly. Two chemotherapy regimens are used for treatment of Malignant Melanoma: single agent intravenous Dacarbazine (DTIC) and oral Temozolomide (TMZ). TMZ has greater cost in Iran so we aimed to do an economic evaluation, to evaluate the comparative value of treatment of two drugs. METHODS: To compare the efficacy of these two drugs, a systematic review and meta-analysis were conducted and published articles, comparing use of single agent Dacarbazine and Temozolomide in treatment of Malignant Melanoma were reviewed. For this purpose, Pubmed, Scopous, Web of Science and Cochrane Central Register of Controlled Trials were searched and the search terms were: "Dacarbazine" and "Temozolomide" and "Malignant Melanoma". Data were collected from inception to 2012. "Response to treatment" includes:" complete response (CR)"," partial response (PR)" and "stable disease (SD)" was the key outcome of interest. The direct cost (drug and administrative procedures costs) was collected from health provider centers. RESULTS: The metaanalysis included 3 RCTS and involved 1314 patients with malignant melanoma. Approximately half of them were allocated to the TMZ arm and half to the DTIC arm. Risk differences for CR was -0.01, for PR was ϩ0.03 and for SD was ϩ0.01. Average cost for one cycle of treatment with TMZ is $1957 and for DTIC is $90 in Iran. For CR based on economic evaluation grid, TMZ treatment is dominated. The incremental CE ratio for PR is $62,233 and ICER for SD is $186,700 respectively. CONCLUSIONS: Considering health outcomes of CR, PR and SD, Temozolomide treatment for melanoma is not cost effective comparing to Dacarbazine in Iran. It should be mentioned that generic Dacarbazine is available in Iran but Temozolomide is provided as branded, and availability to generic form of Temozolomide may affect the results of this economic evaluations.
PCN21 COMPARATIVE EFFECTIVENESS AND COST-EFFECTIVENESS ASSESSMENT OF ERLOTINIB VERSUS GEFITINIB IN FIRST-LINE TREATMENT OF EGFR ACTIVATING MUTATION POSITIVE NON-SMALL CELL LUNG CANCER FOR HONG KONG
The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2 The University of Hong Kong, Hong Kong, Hong Kong, Research and Consulting, Loerrach, Germany OBJECTIVES: To compare the effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor (EGFR) activating-mutation positive (MuTϩ) non-small cell lung cancer (NSCLC) for Hong Kong. METHODS: An indirect treatment comparison (ITC), using the Bucher et al methodology, and a cost-effectiveness assessment (CEA) were performed on the basis of Asian phase-III randomized controlled trials (RCTs). In total four RCTs were determined: one for erlotinib (OPTIMAL) and three for gefitinib (IPASS; NEGJSJ, WJTOG). The CEA model uses a Markov approach that simulates the transition between the health states: progression-free-survival (PFS), progression and death, in monthly cycles over a life-time horizon. The World Health Organization criterion (incremental cost-effectiveness ratio Ͻ 3 times GDP/capita; ϽUSD 102,582; Ͻ,HKDϷ798,078) was used to rate cost-effectiveness. RESULTS: The best fit of study characteristics and of prognostic patient characteristics were found between the OPTIMAL and IPASS trials. Comparing the PFS hazard ratios (HRs) of erlotinib vs. gefitinib using only these RCTs in an ITC resulted in a statistically significant PFS difference in favor of erlotinib (ITC HR: 0.33; 95% confidence-intervals: 0.19-0.58; pϭ0.0001). The CEA model obtained an additional benefit of 0.36 progression-free life years gained and of 0.23 quality-adjusted life years gained (QALYs) by erlotinib, which was accompanied by additional costs of USD 14,061 (HKDϷ109,395). The cost per progression-free life year gained and per QALY gained were USD 39,431 (HKDϷ306,773) and USD 62,419 (HKDϷ485,619) comparing erlotinib vs. gefitinib, respectively. CONCLUSIONS: The ITC of OPTIMAL and IPASS shows that erlotinib is more efficacious when compared to gefitinib. The CEA for Hong Kong shows that the costs per progression-free life year gained and the cost per QALY gained by erlotinib are well within an acceptable range in relation to the survival benefit obtained. Erlotinib is cost-effective compared to gefitinib in first-line EGFR MuTϩ NSCLC.
PCN22
COST-EFFECTIVENESS ANALYSIS OF CERVICAL CANCER SCREENING WITH SELF-SAMPLING FOR HUMAN PAPILLOMAVIRUS (HPV) TESTING IN TAIWAN
Tsai BC 1 , Chow IHI 2 , Liao CH 3 , You SL 4 , Tang CH 1 , Pwu RF 3 1 Taiwan was used in this study. There are three screening tools: 1) Pap smear alone; 2) HPV DNA testing followed by Pap smear triage; and 3) self-sampling for HPV testing followed by Pap smear triage. Self-sampling for HPV testing strategy is annual, and another strategies of screening intervals are annually, every 3 years, and every 5 years. The model parameters are collected from the published references and the health-related governments in Taiwan. Outcome measures included life expectancy, quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratios (ICERs). Probabilistic sensitivity analyses (PSAs) were conducted to assess parameter uncertainty. RESULTS: When three times GDP per capita is used as the decision threshold, and all seven screening strategies were cost-effective compared with the no-screening strategy. Compared with the primary screening strategy (an annual Pap smear), self-sampling HPV testing followed by Pap smear triage, HPV DNA testing followed by Pap smear triage every 5 years and every 3 years were cost-effective. CONCLUSIONS: Self-sampling for HPV testing followed by Pap smear triage is one of the cost-effective screening strategies in Taiwan.
PCN23
COST-EFFECTIVENESS ANALYSIS OF GEFITINIB FOR LUNG CANCER: A POPULATION BASED STUDY
Chien CR 1 , Shih YCT 2 1 China Medical University Hospital, Taichung, Taiwan, 2 The University of Chicago, Chicago, IL, USA OBJECTIVES: Gefitinib is an effective targeted therapy for a subset of non-small cell lung cancer (NSCLC) patients, although its cost-effectiveness remains controversial.. This study used national health insurance claims data to evaluate the costeffectiveness of gefinitib in patients with NSCLC in Taiwan. METHODS: Using claims data and enrollment record from the 2002-2009 National Health Insurance Research Database (NHIRD) in Taiwan, we identified lung cancer patients via the ICD-9-CM codes. We then used ICD-9-CM and billing codes to identify patients who had received chemotherapy containing plantinum-based regimens followed by taxane-based regimens between November 1, 2004 and October 31, 2007. We defined the index date as the date of 1st claim for taxane-based chemotherapy and limited the observational period for cost and survival to 2 years after index date. We further classified these patients into two groups: those who had subsequently received gefitinib vs those had not. We determined survival status by using a previously developed algorithm using the enrollment file of the NHIRD and converted direct medical costs to 2011 US dollars. We then calculated the net benefit for each patient by applying various willingness-to-pay (WTP) values and employed the net benefit regression approach to assess the cost-effectiveness of gefitinib. RESULTS: We identified 2555 lung cancer; 979 (38%) had received gefitinib during our study period. The average cost (standard deviation) were 64150(29482) USD for the gefitinib users and 35925(27360) for non-users. The average survival was 487 days (228) for the gefitinib users and 291 days (248) for non-users. Net benefit regression suggested that gefitinib is cost-effective at WTP 53,000 USD/life-year or higher. CONCLUSIONS: Among lung cancer patients who started with platinum-based chemotherapy, followed by taxane-based regimen, adding gefitinib to chemotherapy is likely to be cost-effective. . Direct and indirect costs, including productivity loss of patients and their accompanying persons caused by receiving outpatient or inpatient services, were involved in this study. Propensity score matching was used to reduce selection bias and avoid endogenous problems between two groups of patients. The perspective adopted in this analysis was that of a society in Taiwan. All costs were expressed in 2011 New Taiwan dollars (1 USD is about 30 NTD). Utility value for the health states were derived by mapping the 16 dimensions of EORTC QLQ-C30 onto the EQ-5D based on the published literature (McKenzie and van der Pol, 2009) . RESULTS: After propensity score matching, a total of 219 patients were included in the analyses. There are 109 in the capecitabine-based treatment and 110 in the 5-FU/LV-based treatment. Over the study period of 6 months, the average cost of capecitabine-based treatment per patient was NT$220,576.3 while yielding 0.47 quality-adjusted life years (QALY). On the other hand, the average cost of 5-FU/LV-based treatment was NT$566,832.1 with 0.42 QALY. Between these two adjuvant treatments, the capecitabine-based treatment was dominant. CONCLUSIONS: As opposed to existing studies, cost and HRQoL data were directly obtained from patients. Thus, based on patient-level information and the from the societal perspective, our study showed that capecitabine-based treatment not only saved costs but also improved quality-adjust life year compared with 5-FU/LVbased treatment in the adjuvant treatment of stage III colorectal cancer in Taiwan.
PCN24 HEALTH RELATED QUALITY OF LIFE, DIRECT AND INDIRECT COST ANALYSIS OF STAGE III COLORECTAL CANCER PATIENTS RECEIVING DIFFERENT ADJUVANT CHEMOTHERAPY TREATMENTS IN TAIWAN: A COST UTILITY ANALYSIS
CANCER -Patient-Reported Outcomes & Patient Preference Studies
PCN25 UTILITY OF ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS IN THAILAND: PRELIMINARY STUDY
Tongpak P 1 , Thongprasert S 2 , Permsuwan U 3 1 Kasetsomboon Hospital, Kasetsomboon , Chaiyaphum , Thailand, 2 Faculty of Medicine Maharaj Nakorn Chiang Mai Hospital, Meung, Chiang Mai, Thailand, 3 Faculty of Pharmacy Chiang Mai University, Meung, Chiang Mai, Thailand OBJECTIVES: Lung cancer is the common cause of cancer death in developing countries. In Thailand, lung cancer, including non-small cell lung cancer (NSCLC) ranks third of 10 leading sites of cancers. NSCLC has a poor prognosis which has an effect on quality of life of both individual patients and their family. Understanding the quality of life and health utility for lung cancer is important; however, little data are available in Thailand. This study aimed to measure baseline health utility among advance NSCLC patients before treated with first-line chemotherapy. METHODS: A prospective cohort study was implemented in Maharaj Nakorn Chiang Mai hospital which is a medical teaching hospital located in the north of Thailand. A variety of first-line chemotherapy regimens were available for treatment. In this study, we included patients aged 18 or above, diagnosed with NSCLC with stage IIIB and IV, had performance status (ECOG) 0-1, and were scheduled to receive first-line chemotherapy. The data were collected from January to March 2012. Utility was measured using EuroQoL Thai version. The data were collected while patients visited outpatient oncology clinic. Descriptive statistics were used for data analyses. RESULTS: During three months period, 24 patients were included. Eight patients were NSCLC stage IIIB while 16 were stage IV. Mean utility value of overall NSCLC, NSCLC stage IIIB and NSCLC stage IV at baseline before receiving first-line chemotherapy were 0.419, 0.473 and 0.392, respectively. CONCLUSIONS: Utility values of patients with advanced NSCLC are likely to be downward due to the severity of disease; therefore, choosing the appropriate firstline chemotherapy regimen might need to consider the quality of life of patients. OBJECTIVES: Benefits of treatment are often expressed as quality-adjusted life years (QALYs). A QALY attempts to capture benefit in terms of both quantity of survival and quality of life (QoL). Where appropriate data has not been captured in a trial context, other methods need to be applied. The aim of this study was to capture QoL data in the form of health state utilities, ranging from 0 (dead) to 1 (full health), for outcomes associated with receiving therapy for rel/ref HL and sALCL. These utilities could be used to support economic evaluation of future treatments. METHODS: Health state descriptions or 'vignettes' were developed (with patient and clinician input) depicting the burden associated with various stages of rel/ref HL or sALCL, degree of disease response (complete [CR] or partial response, stable or progressive disease), and adverse events (AE) experienced (B-symptoms, acute/ chronic graft-versus-host disease [GVHD], grade I/II or grade III peripheral sensory neuropathy). Vignettes were then valued by 75 members of the general public in Taiwan, Thailand, and South Korea using the time trade-off (TTO) methodology to elicit utility values. RESULTS: Disease experience was associated with a significant decline in QoL. Even a CR demonstrated a notable negative impact on QoL (Taiwan 0.597, Thailand 0.728, South Korea 0.827). The experience of any AE was associated with substantial disutility, the most burdensome generally being acute GVHD (Taiwan 0.199, Thailand 0.124, South Korea 0.347). Additionally, progressive disease was valued as having a very severe impact on QoL (Taiwan 0.229, Thailand 0.071, South Korea 0.317). CONCLUSIONS: Experience of rel/ref HL and sALCL is viewed as potentially devastating by individuals in all three countries. However, variations do exist between regions, suggesting that individuals may approach the TTO exercise differently. The results of this study may have important implications for the economic evaluation of future treatments.
PCN26 HEALTH STATE UTILITIES FOR RELAPSED/REFRACTORY (REL/REF) HODGKIN'S LYMPHOMA (HL) AND SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA (SALCL): ASIAN PACIFIC COUNTRY DATA
PCN27 DISCLOSING COMPLEMENTARY AND ALTERNATIVE MEDICINES (CAM) USE TO THE HEALTH CARE PROVIDERS:A DESCRIPTIVE STUDY
